Systemic scleroderma-also known as systemic sclerosis (SSc)-is a chronic systemic connective tissue disease characterized by collagen deposition in cutaneous and internal organs, leading to skin sclerosis and multiple organ fibrosis. The pathogenesis is complex and remains poorly understood. Treatment is based on organ involvement and requires a multidisciplinary approach. Skin sclerosis can cause disability, leading to decreasing quality of life. Various systemic antifibrotic therapies have been used; however, most have unsatisfactory results. Recently, phototherapy and in particular ultraviolet A (UVA) has been used to treat skin sclerosis in SSc patients with satisfactory results. The main mechanisms include lymphocyte apoptosis, cytokine alteration, inhibition of collagen synthesis and increased collagenase production, and neovascularization, leading to the breakdown of collagen fibrils resulting in skin softening or even healing digital ulcers. Most studies reported that psoralen plus UVA (PUVA) and UVA1 phototherapy improved clinical outcomes vis-à-vis skin sclerosis, joint mobility, ulcers, and histopathology. PUVA and UVA1 phototherapy therefore have potential as an alternative or adjunctive therapy for patients with SSc.
extremities, while diffuse scleroderma (diffuse cutaneous systemic sclerosis-dcSSc) involves the trunk and both proximal extremities. 24 The disease varies in clinical features depending on the type and stage (early or late) of the disease and different autoantibodies.
The diagnosis of SSc was previously based on clinical findings as per the 1980 American College of Rheumatology (ACR) criteria. 25 This required 1 major criterion (ie, proximal scleroderma characterized by skin-thickening proximal to the metacarpal phalangeal joints) or 2 or more minor criteria (viz., sclerodactyly, digital pitting scars or loss of the distal finger fat pad, and bilateral basilar pulmonary fibrosis). 25 It was challenging to diagnose patients in early disease, especially with minimal or limited skin sclerosis without proximal scleroderma or pulmonary involvement. In 2013, a joint committee of the ACR and the European League Against Rheumatism (EULAR)
proposed new classification criteria with higher sensitivity enabling early diagnosis in clinical settings. 26 These criteria included clinical features, SSc-specific autoantibodies, and nail-fold capillary abnormalities. 26 There have been various methods for severity assessment of SSc (Table 1) ; however, the modified Rodnan skin score (MRSS) remains the standard tool and the most commonly used in clinical trials. 27, 28 All of these tools should be evaluated by a single examiner for consistency.
| PATHOGENESIS OF THE DISEASE
The etiology and pathogenesis of scleroderma remain unclear. There are 3 key pathogenic components comprising the interplay between the systems and pathogenesis: small vessel vasculopathy, immune system abnormalities, and tissue fibrosis ( Figure 1 ). 29, 30 There is no evidence on which process occurs first, and this is complicated by the fact that other factors influence pathogenesis (ie, genetic susceptibility, epigenetic abnormalities, and environmental factors). [29] [30] [31] Endothelial injury is believed to be an early event in the pathogenesis of SSc. 32 Damaged endothelial cells release chemokines leading to inflammatory cell infiltrate in affected areas as can be seen in the early stage of disease. 33 SSc is hypothesized to be an autoimmune disease because (i) 90%-95% of patients with scleroderma have circulating antinuclear antibodies 34 and (ii) SSc-related specific autoantibodies are detected. SSc can moreover be found in overlap with systemic lupus erythematosus, rheumatoid arthritis, polymyositis, and Sjogren's syndrome. 32 These observations taken together support the hypothesis; however, the exact cause and origin of antibody production is not known.
Activated lymphocytes, macrophages, endothelial cells, and fibroblasts release profibrotic cytokines, chemokines, growth factors, and interleukins, all of which contribute to fibrosis. 33, 35, 36 TGF-β, which is a strong profibrotic cytokine produced by fibroblasts, T cells, macrophages, and platelets, plays a key role in the fibrotic process by promoting migration and differentiation of fibroblasts into myofibroblasts, leading to collagen production and accumulation of extracellular matrix protein. 37 In later stages, the inflammatory cells disappear and are replaced by densely collagen in the dermis together with loss of microvasculature and reduction of skin appendages.
| PHOTOTHERAPY: MECHANISM OF ACTION
Ultraviolet irradiation (UVR) comprises ultraviolet C (UVC) (with wavelengths 200-290 nm), ultraviolet B (UVB) (290-320 nm), and ultraviolet A (UVA) (320-400 nm). UVA is further classified into UVA2
(320-340 nm) and UVA1 (340-400 nm). Only UVB and UVA reach the earth's surface, whereas UVC is absorbed by the ozone layer. The longer wavelengths can penetrate deeper into the dermis and cause less sunburn side-effects than shorter wavelengths. UVA penetrates into the deep dermis and rarely causes sunburn, while UVB penetrates only into the upper dermis and easily causes sunburn.
UVA wavelength has been used to treat sclerotic skin disease because of the deeper penetration. The mechanism of photochemotherapy with psoralen plus UVA irradiation (PUVA) and UVA1 phototherapy for treatment of SSc derives from lymphocyte apoptosis, cytokine alteration, inhibition of collagen synthesis and increased collagenase production, and neovascularization ( Figure 1 ). PUVA and UVA1 irradiation can induce several different kinds of cytokine production; however, some cytokines may be reported differently from study to study. PUVA reduces interleukin (IL)-4 and IL-10 (Th2 cytokines), and increases interferon-gamma (IFN-γ) and IL-2 (Th1 cytokines) in peripheral blood lymphocytes and monocytes. 43 The activated monocytes also produce IL-8. 44 One study showed that UVA1 irradiation reduced TNF-α from suction blister fluid at the irradiated site compared with nonirradiated skin; 46 however, another study demonstrated that TNF-α increased after UVA1 irradiation in human epidermoid carcinoma cell line. 45 TNF-α is able to reduce type I and III collagen production by inhibiting the mRNA levels of collagens and of fibronectin, and increasing collagenase production and collagenase mRNA levels in scleroderma fibroblasts. 45 UVA1 exposure induces keratinocytes secreting IL-8; 46-48 however, another study showed that UVA1 irradiation decreases IL-8, IL-6, and human beta-defensins in the lesion of localized scleroderma. 49 UVA1 can also induce transurocanic acid (UCA) isomerization to cis-UCA, which has immunosuppressive effects.
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PUVA and UVA1 exposure can both reduce collagen production representing an antifibrotic effect. Whereas PUVA reduces type I and III collagen synthesis, 51 UVA (320-400 nm) induces interstitial collagenase (MMP-1) synthesis in human dermal fibroblast through protein kinase C-, cAMP-dependent protein kinase-, Src family tyrosine kinase-, mitogen-activated protein kinase-, c-Jun-, and AP-1-dependent pathways, 52, 53 and via induction of IL-1 and IL-6. 54 In an in vitro study, UVA1 irradiation induces MMP-1 in SSc fibroblasts. 55 MMP-1 is the major protease that initiates degradation of the fibrillar collagens type I and III into specific fragments which are further hydrolyzed by MMP-3
and MMP-9 resulting in collagen reduction. 56 UVA1 exposure reduces decorin-the major proteoglycan involved in fibrinogenesis-in the F I G U R E 1 Schematic pathogenesis of systemic sclerosis and effect of phototherapy on disease. CTGF, connective tissue growth factor; IL, interleukin; MMP, matrix metalloproteinase; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α upper to mid-dermis of patients with SSc. 57 UVA1 irradiation impairs TGF-β/Smad pathways through downregulation of mRNA expression of TGF-β1 and Smad3/4/7 in human skin in vivo, while UVB does not have this effect. 58 UVA1 irradiation also significantly reduces TGF-β1 levels in fibroblasts. 58 Moreover, UVA1 irradiation can induce neovascularization and decrease endothelial apoptosis in SSc by modulation of endothelial regulation and transformation. 59 Thus, PUVA and UVA1 phototherapy can reduce skin sclerosis through the foregoing mechanisms; however, lymphocyte apoptosis has a beneficial effect at an early stage of SSc, while collagenase production is the main effect in the late stage of disease.
Although UVB penetrates less deep than UVA, UVB irradiation can induce collagen reduction. After UVB exposure, keratinocytesanother major source of MMPs in human skin besides fibroblasts-release MMP-1 through direct DNA damage and/or stimulate fibroblasts to produce MMP-1 via cytokines and other soluble factors. 56, 60 UVB irradiation also reduces expression of TGF-β1 and type I collagen at the mRNA and protein levels in cultured human skin fibroblasts.
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A randomized controlled study comparing the efficacy of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in patients with localized scleroderma demonstrated that all three treatments significantly improve skin sclerosis, and narrowband UVB phototherapy is as effective as low-dose UVA1. 62 Another randomized, split-scalp comparison study demonstrated that targeted UVB phototherapy significantly reduces the mean number of acne keloidalis nuchae lesions. 63 Notwithstanding, there has been no study of narrowband UVB phototherapy for systemic sclerosis; perhaps due to concern over photosensitivity of connective tissue to UVB thus favoring the use of UVA.
| PHOTOTHERAPY IN SYSTEMIC SCLEROSIS
In 1995, photochemotherapy with topical psoralen plus UVA irradiation (PUVA) was used to treat a patient with SSc for the first time and the results showed that the patient responded well (ie, both clinically and histologically). 3 After that topical PUVA, bath PUVA, oral PUVA, and UVA1 were used to study treatment response in patients with SSc. Phototherapy for patients with SSc is being actively investigated (Table 2) ; all studies used UVA wavelength for treatment of skin sclerosis in patients with SSc because UVA can penetrate into the deep dermis better than UVB, and maybe the concern over UVB-induced photosensitivity in connective tissue disease. Most studies comprised of case reports, case series, and uncontrolled trials support the hypothesis that PUVA therapy improves clinical outcomes in terms of (i) skin sclerosis, (ii) joint mobility, (iii) histology, (iv) serology, and (v)
immunohistochemistry. [3] [4] [5] [6] [7] [8] [9] [10] [11] Not only topical PUVA but also bath and oral PUVA reduced skin thickness. [4] [5] [6] 9 A case series reported that 9 of 12 patients with SSc treated with bath PUVA had skin improvement albeit 2 patients had no clinical improvement. 5 Interestingly, 1 of 12 cases receiving corticosteroids and pentoxifylline together with bath PUVA had completely improved skin sclerosis within 6 months. 5 It is difficult to conclude that skin sclerosis was completely resolved by PUVA alone as corticosteroids and pentoxifylline also have an antifibrotic effect. [64] [65] [66] Nevertheless, it appears that a combination of antifibrotic treatments may have a synergistic effect and could markedly reduce skin sclerosis. Shortly thereafter, a prospective, uncontrolled study showed that oral PUVA therapy improved subjective overall status in 3 of 4 patients; however, there was no significant difference in the respective skin severity score, joint motility, grip strength, or ultrasonography before and after treatment in all 4 patients. 6 In be due to a reduction in, and remodeling of, collagen via an increase in matrix metalloproteinase that improves blood circulation through these areas. 67 Most of the PUVA studies support its beneficial effect on SSc. It should be noted that the studies are case reports, case series, and uncontrolled studies which have a small number of patients.
Not only PUVA but also broadband UVA has been used to treat skin sclerosis in SSc; however, there is only 1 case report demonstrating that UVA phototherapy reduced skin sclerosis in SSc.
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UVA1 has been widely used for treating sclerotic skin disease including SSc. The dose of UVA1 is divided into 3 categories based on radiation sources: low, medium/moderate, and high dose. Fluorescent lamp cubicles allow for treatment with low to medium dose, while high-output metal halide sources allow for high-dose treatment. 
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(i) improved clinical hand sclerosis, (ii) decreased collagen thickness in histology, (iii) decreased skin thickness by ultrasound, (iv) increased skin distension by cutometer, (v) induced increased MMP-1 levels, and (vi) decreased inflammatory cell infiltrates in the dermis after treatment. 16 These observations support the hypothesis that UVA1 has a direct effect on skin-infiltrating lymphocyte apoptosis and induction of MMP-1, leading to enhanced collagen breakdown. Additionally, a case series showed that 1 of 3 patients had complete remission of skin sclerosis after treatment with low-dose UVA1 (35 J/cm 2 ).
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In addition to low-dose UVA1, several studies reported the benefit of medium-and high-dose UVA1 for treatment of SSc. A prospective, uncontrolled study using medium-dose UVA1 (60 J/cm 2 ) for treatment of 4 patients with SSc demonstrated that all 4 patients had marked clinical improvement, including of skin sclerosis and elasticity, joint passive range of motion, and temperature, and 3 of 3 patients had histological improvement. 13 In another study, 1 case showed that medium-dose UVA1 (50 J/cm . 23 These studies support the benefit of low-, medium-, and high-dose UVA1 for treatment skin sclerosis in patients with SSc; however, high dose seems more effective than medium to low dose. 23 There has been no randomized controlled trial to evaluate and compare the efficacy among these doses of UVA1, so further study is needed.
By contrast, a randomized, investigator-blinded, controlled study using a half-side comparison of 9 SSc patients with UVA1 40 J/cm 2 3 times per week for 14 weeks showed no difference in either the skin score or visual analog scale between treated and untreated hands, and no statistical difference for index flexion and extension.
Only 2 of the patients in the study experienced marked improvement of hand function after treatment. 18 The results could be an artifact of the small number of patients, so the study lacks power. This study did not, however, describe the method for protecting untreated hands during irradiation. Notably, this study found that duration of disease did not correlate with response to treatment which was similar to previous studies. 13, 16 Relatedly, most of the studies have a small number of patients and are open, nonrandomized studies due to the fact that phototherapy in SSc is highly experimental which may indicate a publication bias. Randomized controlled studies with large number of patients are needed.
Some studies reported the use of UVA1 phototherapy together with other immunosuppressive drugs (ie, mycophenolate mofetil, pulsed cyclophosphamide, methotrexate and ciclosporin, and azathioprine) and showed good results. 16, 20 Immunosuppressive side-effects and skin cancer remains a concern, so short maintenance therapy may be safer than prolonged treatment. T A B L E 2 (Continued)
PUVA and UVA1 therapy can cause short-and long-term sideeffects. The short-term side-effects include erythema, pruritus, and skin tanning, while long-term effects include lentigines, photoaging, and carcinogenicity. The risks of UVA1-induced carcinogenicity are, however, unclear, while the risks of PUVA-induced actinic keratoses and non-melanoma skin cancer (particularly squamous cell carcinoma) correlate with cumulative UVA dose/number of PUVA exposures. 69 Systemic PUVA therapy can cause gastrointestinal side-effects, dizziness or headache after taking oral 8-MOP. 69 The side-effects can be avoided by switching to 5-MOP. Although there are many side-effects of phototherapy from PUVA and UVA1, they are less severe than other systemic immunosuppressive treatments. The major concern vis-à-vis PUVA side-effects is skin cancers; however, the risk of cancer can be reduced by carefully monitoring the cumulative dose and watching for development of any precursors to skin cancers.
Due to the cost and therefore limited access to UVA1 therapy, PUVA therapy has been more widely used than UVA1. Research has demonstrated that PUVA therapy can also be used to treat skin sclerosis as effectively as UVA1 treatment as the peak action spectrum of broadband UVA is 370 nm (UVA1 wavelength) 70 and most energy (90%) emits from the UVA1 wavelength. 71 Notwithstanding, the sideeffects from PUVA therapy seem greater than the UVA1 treatment, so randomized controlled studies comparing the efficacy and longterm outcomes of PUVA and UVA1 treatment in patients with SSc are needed.
| CONCLUSION
To date, there are no effective treatments for skin sclerosis in SSc. Randomized controlled studies including large number of patients and standard objective measurement are needed to confirm the efficacy of phototherapy for patients with SSc.
